AHCO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
AdaptHealth Corp (AHCO) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 to invest. The company's financial performance is weak, technical indicators suggest a bearish trend, and there are no strong proprietary trading signals. While hedge funds are buying and the company has achieved some operational improvements, the negative catalysts outweigh the positives, making it prudent to hold off on buying this stock for now.
The MACD is negative and expanding (-0.147), indicating bearish momentum. RSI is at 31.005, close to oversold but still neutral. Moving averages are converging, showing no clear trend. The stock is trading below its pivot point (9.631), with support at 8.869 and resistance at 10.393. Overall, the technical indicators suggest a bearish trend.
Hedge funds are significantly increasing their positions, with a 1321.21% increase in buying over the last quarter. The company achieved operational improvements and secured a major capitation contract in the DME industry.
The company is under investigation for potential breaches of fiduciary duties, which could harm shareholder confidence. Financial performance in Q4 2025 showed significant declines in revenue (-1.21% YoY), net income (-317.56% YoY), and gross margin (-45.68% YoY). Analysts have lowered price targets, and the stock has underperformed recently, with a -2.68% regular market change.
In Q4 2025, revenue was $846.3 million, down -1.21% YoY. Net income dropped significantly to -$100.08 million (-317.56% YoY), and EPS fell to -$0.74 (-317.65% YoY). Gross margin also declined to 19.17% (-45.68% YoY). While revenue guidance for FY26 is positive ($3.44 billion to $3.51 billion), the company's financial health remains concerning.
Deutsche Bank lowered its price target from $10.50 to $9.50 and maintained a Hold rating. Canaccord reduced its price target from $15 to $14 but maintained a Buy rating, citing operational improvements but also noting challenges such as a legal settlement and ramp-up costs for a new contract.
